Question 1

What is the Semax peptide?

Accepted Answer

Semax is a short synthetic peptide copied from part of a human hormone, with a small tail added so it lasts longer. A 2016 chemistry paper gives the structure plainly. Semax is a heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) that encompasses the sequence 4-7 of N-terminal domain of the adrenocorticotropic hormone and a C-terminal Pro-Gly-Pro tripeptide. That hormone is usually shortened to ACTH, and it is the signal that tells the adrenal glands to release stress hormones. The important part is what the copy leaves out. A 2024 rat study calls Semax and a related compound noncorticotropic synthetic analogs of the ACTH(4-10) fragment, so they carry the shape of a hormone without acting as one. A 2000 Russian paper calls it a synthetic analog of adrenocorticotropic hormone 4-10 with a pronounced nootropic effect. Nootropic is the word that literature uses for something meant to sharpen thinking, so it names an intention rather than a result.

Question 2

What is Semax used for?

Accepted Answer

In Russian clinical practice it is a stroke compound. Everywhere else it is a research compound with no approved use. A 2010 paper states that the polypeptide Semax is successfully used for acute stroke therapy. A 2014 genomics paper repeats the claim, saying the nootropic neuroprotective peptide Semax has proved efficient in the therapy of brain stroke. A 2008 cell study adds the second use, noting that Semax is known to stimulate learning and memory and can be successfully used for treatment of ischemic stroke. Two older Russian papers describe eye conditions instead. One applied it in vascular, toxic allergic, and inflammatory diseases of the optic nerve and partial atrophy of the optic nerve, alongside standard therapy. The other used it in glaucoma patients with normalized ophthalmic tone. Notice the shape of all four sentences. They assert that the compound is used, not that a controlled trial established it should be. Those are different claims, and the second is thinner than the first.

Question 3

Where does the Semax evidence come from?

Accepted Answer

Nearly all of it was produced within a single research community, which matters for how much weight a reader gives it. The source titles say so directly. A 2000 ophthalmology paper is an evaluation of the therapeutic effect of the new Russian drug semax in optic nerve disease. A 2001 paper from the same journal calls it a new Russian neuropeptide semax. A 2009 pharmacology paper lists it among clinically used drugs piracetam, phenotropil, meclophenoxate, and semax, three of which are unfamiliar outside that setting. The journals follow the same pattern. The human studies appear in Vestnik Oftalmologii, the Korsakov neurology journal and the Bulletin of Experimental Biology and Medicine. The animal work sits in Acta Naturae, Biochemistry (Moscow) and Izvestiya Akademii Nauk. None of this passes judgement on the research itself. It is a point about replication. A finding reproduced by groups who do not share methods, assumptions or reagents is stronger than the same finding repeated inside one tradition, and the second is what this literature mostly offers.

Question 4

Does Semax actually work?

Accepted Answer

The best human evidence is one study of 110 people, and its design decides how much weight it carries. One hundred and ten patients after ischaemic stroke were examined, 43 men and 67 women, with a mean age of 58. All patients were divided into early and late rehabilitation groups, and each group was subdivided into semax+ and semax- subgroups. Administration of semax, regardless of the timing of rehabilitation, increased BDNF plasma levels in these patients, which remained high during the whole study period. The authors conclude that early rehabilitation and administration of semax increase BDNF plasma level, speed functional recovery, and improve motor performance. Now read the design. There is no placebo, no blinding and no randomisation described, and everyone knew which subgroup a patient was in. A blood protein going up is a real measurement; a recovery score in an unblinded study is not the same kind of evidence. A 2026 orthopaedic review covering neuroactive peptides including semax records the broader position in one line: there is a current lack of clinical trials.

Question 5

Has Semax been tested in people?

Accepted Answer

Five times, in published work, and two of those five were properly controlled. The controlled pair are brain-imaging studies in healthy people. The larger one assessed effects of anxiolytic Selank and nootropic Semax on the whole-brain resting-state functional connectivity in 52 healthy participants, with scanning before, after 5 and 20 min of the injection of either Semax, or Selank, or placebo. The smaller one scanned two groups of healthy volunteers (11 men and 13 women aged 43.9 years on average), giving intranasal 1% Semax (14 subjects) or placebo (10 subjects). A greater volume of the default mode network rostral (medial frontal cortex) subcomponent was detected in the Semax group in comparison with controls. The other three are the 110-patient stroke study and the two Russian eye papers from 2000 and 2001. Weigh what the controlled ones measured. Both imaging studies found a difference in how brain regions co-activate at rest. That is a signal that something reaches the brain, rather than evidence that anything useful follows.

Question 6

Does Semax do anything if nothing is wrong?

Accepted Answer

No question in the literature is more useful than this one, and it is the animal studies, more than the human ones, that answer it. A 2010 rat study tested the compound in both states. Semax administration did not influence the emotional state of animals in the normal state. When anxiety and low mood were induced with a separate compound, Semax normalized the animal behavior disturbed by that administration. A 2009 mouse study found the same pattern. Changes in the BDNF level were only observed in the hippocampus of the lower-performing mice, and the authors conclude that semax realizes its effect via increase in hippocampal BDNF level, which is achieved only under conditions of cognitive deficiency. A 2024 study still leaves the healthy case open, noting that it is necessary to study influence of the peptide on the brain cells under normal physiological conditions, including understanding the risks of their use. Fixing a deficit is one question, and making a healthy system work better is another. The animal work has repeatedly found the first and repeatedly failed to find the second.

Question 7

Does Semax act like a stimulant?

Accepted Answer

No study among the research behind this page has compared Semax with a stimulant, or measured alertness, heart rate or sleep in a person taking it. What the animal work shows is the opposite profile. A stimulant acts on a brain that is already working normally. In the 2010 rat study, the compound did nothing to animals in the normal state, and only did something once their behaviour had been disturbed. The 2009 mouse study reached the same conclusion from brain-protein measurements, finding an effect only under conditions of cognitive deficiency. The receptor work points the same way. A 2019 rat study showed the ability of Semax to modulate in a dose-dependent manner acetylcholine and GABA specific binding to some of its corresponding receptors. Modulating a receptor's binding is a quieter kind of action than flooding a synapse, which is what stimulant compounds do. So the honest answer is that no study we could find has run the comparison, and the animal evidence points away from a stimulant-like profile rather than towards one.

Question 8

Does Semax mess with hormones?

Accepted Answer

No study among the research behind this page reports a hormone panel in a person given Semax. It is built from a hormone fragment, which is why the question keeps coming up. The literature's own answer is that the hormone part was left out on purpose. A 2024 rat study calls Semax one of the noncorticotropic synthetic analogs of the ACTH(4-10) fragment. It has the shape without the hormone-releasing action. Two rodent experiments did measure a stress hormone, and both used stressed animals rather than healthy ones. In Wistar male rats held still, administration of the peptide led to a decrease in corticosterone concentration. Corticosterone is the rat version of cortisol. In a second model, chronic treatment with Semax attenuated adrenal hypertrophy, the swelling of the adrenal glands that long stress produces in rats. Both findings show a stress response pulled back towards normal, not a hormone pushed up or down. Neither has been measured in a person.

Question 9

Does Semax cause weight gain?

Accepted Answer

No study among the research behind this page has measured body weight in a person given Semax. One rat study measured it, and the result runs in a direction most readers will not expect. The 2024 chronic stress study used body weight as an outcome. Stressed and control male adult Sprague-Dawley rats received daily injections, and rats were monitored for BW and hedonic status, as measured in the sucrose preference test. Hedonic status means whether an animal still bothers to seek something pleasant. Chronic stress had suppressed the animals' normal weight gain. Chronic treatment with Semax reversed or substantially attenuated that stress-induced BW gain suppression, alongside the loss of interest in sucrose. Read that carefully, because the direction matters. Semax did not add weight to a healthy rat. It restored growth that stress had taken away, in rats that had stopped gaining weight normally. Restoring suppressed weight gain in a stressed rat and causing weight gain in a person are different questions, and the second has not been asked.

Question 10

Can Semax be addictive?

Accepted Answer

No study among the research behind this page has measured dependence, tolerance or withdrawal in anyone given Semax, and no animal study on record was built to look for them. One finding makes the question reasonable rather than idle. A 2025 mouse study of spinal cord injury used network pharmacology and docking, which are computational methods for predicting what a molecule binds to, and that analysis revealed the μ-opioid receptor as a Semax target. The experiment then found that Semax promoted recovery in those mice by targeting μ-opioid receptors, which regulated a protein called USP18. That is the receptor family morphine acts on, so the question is fair. It is also a long way from an answer. A molecule touching a receptor and a person finding it hard to stop are different questions. Nothing in the Russian clinical literature reports craving, escalating use or a withdrawal syndrome, and nothing in it was designed to detect any of the three.

Question 11

How is Semax given in studies?

Accepted Answer

Human studies mostly use the nose. Animal studies mostly use a needle. That split runs through the whole literature and no study among the research behind this page has compared the two directly. On the human side, a 2006 rat paper notes that the peptide after intranasal application has profound effects on learning, and the imaging study in healthy volunteers used intranasal 1% Semax. The 2000 ophthalmology study used two nasal routes at once: in group 1 semax was administered intranasally as nasal drops, in group 2 by endonasal electrophoresis, which drives the compound through tissue with a small current. The animal work generally injects. The restraint-stress study used intraperitoneal administration, meaning into the abdominal cavity, and the chronic stress study did the same. One paper raises a third option. A 2005 review of these peptides argues that the ability of glyprolines to pass gastro-enteric tract barriers opens ways to per-oral administration, meaning by mouth, though no human study has tested that route. The nose and the needle are different ways into the brain rather than interchangeable ones, and no study in these sources has run that comparison. Amounts, schedules and routes are set out at the Semax dosage page.

Question 12

Is Semax approved anywhere?

Accepted Answer

In Russia the literature describes it as a medicine already in use. Outside Russia it has no approval at all. The Russian side is stated rather than argued. A 2000 ophthalmology title calls it the new Russian drug semax, a 2001 paper calls it a new Russian neuropeptide semax, and a 2009 pharmacology paper lists it among clinically used drugs. A 2025 paper from the same tradition refers to the peptide drug Semax and its derivative. Nothing in that establishes a Western approval. A 2026 gerontology review searched PubMed, Scopus and regulatory databases (FDA, WADA) and sorted its nine peptides into approved and non-approved groups. Its finding for the second group is that non-approved peptides showed promising preclinical and limited clinical evidence but lack long-term safety data and systematic validation. An approval in one country is a real fact but not a transferable one: it says one regulator accepted a dossier, and nothing about what another would make of the same evidence.

Question 13

Is Semax safe?

Accepted Answer

No controlled study has set out to measure harm from Semax over any length of time, and reported clinical use in one country is not the same thing as a safety dataset. A 2026 gerontology review that searched FDA and WADA records states the position for the non-approved peptides it covered: they lack long-term safety data and systematic validation. The literature's own framing is worth noticing. A 2025 Russian paper explains the interest in compounds like this by describing natural peptide drugs lacking side effects. That is a motivation for studying them, not a measurement taken from anybody. A 2024 study is more careful, saying it is necessary to study influence of the peptide on the brain cells under normal physiological conditions, including understanding the risks of their use. That sentence is from 2024, about a compound reported in clinical use for decades. Interactions, daily use and organ-specific questions are taken one at a time at the Semax safety page.

Question 14

How does Semax work?

Accepted Answer

The proposed route runs through BDNF, a protein that helps nerve cells grow and survive, and almost every step of it was measured in rodent brain tissue. A 2006 rat study is the clearest single piece. A single application of Semax results in a maximal 1.4-fold increase of BDNF protein levels in rat hippocampus, with a matching rise in the activation of its receptor. The authors suggest that Semax affects cognitive brain functions by modulating the expression and the activation of the hippocampal BDNF/trkB system. After a stroke the pattern is selective. In rats, Semax enhanced the transcription of Bdnf, TrkC, and TrkA 3 h after occlusion, and selectively affected the transcription of neurotrophins and their receptors in the ischemic rat cortex. A genome-wide study in rats found something less expected. The peptide predominantly enhanced the expression of genes related to the immune system in rat brain tissue, So the account is a rodent gene-expression story with one human blood measurement attached.

Semax